Atara Biotherapeutics' CEO Pascal Touchon discusses his company's approved allogeneic cell therapy, and the EBV theory of MS.

Arcellx CMO Chris Herry talks about BCMA CAR-T for multiple myeloma at #JPM23.

Seagen's David Epstein talks about antibody-drug conjugates at #JPM23.

Generate Biomedicine's Mike Nally describes how AI might impact biotech in the future at #JPM23.

Moderna CEO Stéphane Bancel discusses his company's personalized cancer vaccine on Day Two of #JPM23 in San Francisco.

Caribou Biosciences's CEO Rachel Haurwitz talks about her company's allogeneic CD19 CAR-T program that has a PD-1 knockout.

Kite’s Kristi Shaw discusses BCMA, moving CAR-T into earlier lines of treatment, and focusing on improving auto programs.

John Oyler discusses BeiGene's BTK inhibitor Brukinsa and cautions about the Inflation Reduction Act.

Immunocore's Bahija Jallal talks about TCR based therapies at #JPM23.

John Evans talks about base editing as a tool for genetic diseases and cell therapy engineering.

Flagship Pioneering's Noubar Afeyan describes what it was like to navigate the pandemic as Chairman of Moderna.